FULC Stock Summary and Trading Ideas (Fulcrum Therapeutics | NASDAQ:FULC)

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Fulcrum Therapeutics trades on the NASDAQ stock market under the symbol FULC.

As of June 4, 2026, FULC stock price climbed to $3.25 with 2,427,861 million shares trading.

FULC has a beta of 0.50, meaning it tends to be less sensitive to market movements. FULC has a correlation of 0.01 to the broad based SPY ETF.

FULC has a market cap of $216.45 million. This is considered a Small Cap stock.

In the last 3 years, FULC traded as high as $15.74 and as low as $2.32.

The top ETF exchange traded funds that FULC belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.

FULC has underperformed the market in the last year with a price return of -53.8% while the SPY ETF gained +28.0%. FULC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -58.7% and -48.8%, respectively, while the SPY returned +11.4% and +2.0%, respectively.

FULC support price is $3.06 and resistance is $3.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FULC shares will trade within this expected range on the day.